- Home
- KZR vs BOLD Comparison
KZR vs BOLD Comparison
Compare KZR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- BOLD
- Stock Information
- Founded
- KZR 2015
- BOLD 2018
- Country
- KZR United States
- BOLD United States
- Employees
- KZR N/A
- BOLD N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- KZR Health Care
- BOLD
- Exchange
- KZR Nasdaq
- BOLD Nasdaq
- Market Cap
- KZR 29.7M
- BOLD 33.4M
- IPO Year
- KZR 2018
- BOLD 2024
- Fundamental
- Price
- KZR $6.19
- BOLD $1.40
- Analyst Decision
- KZR Hold
- BOLD Buy
- Analyst Count
- KZR 4
- BOLD 4
- Target Price
- KZR $6.00
- BOLD $4.00
- AVG Volume (30 Days)
- KZR 456.4K
- BOLD 200.8K
- Earning Date
- KZR 11-11-2025
- BOLD 11-05-2025
- Dividend Yield
- KZR N/A
- BOLD N/A
- EPS Growth
- KZR N/A
- BOLD N/A
- EPS
- KZR N/A
- BOLD N/A
- Revenue
- KZR N/A
- BOLD N/A
- Revenue This Year
- KZR N/A
- BOLD N/A
- Revenue Next Year
- KZR N/A
- BOLD N/A
- P/E Ratio
- KZR N/A
- BOLD N/A
- Revenue Growth
- KZR N/A
- BOLD N/A
- 52 Week Low
- KZR $3.53
- BOLD $1.00
- 52 Week High
- KZR $8.45
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- KZR 79.24
- BOLD 62.14
- Support Level
- KZR $5.95
- BOLD $1.23
- Resistance Level
- KZR $4.45
- BOLD $1.55
- Average True Range (ATR)
- KZR 0.31
- BOLD 0.09
- MACD
- KZR 0.24
- BOLD 0.02
- Stochastic Oscillator
- KZR 92.67
- BOLD 55.88
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.